ABSTRACT:
For simultaneous evaluation of glycopyrronium, vilanterol, and fluticasone furoate in capsules, an Inertsil ODS C18 column was used to develop a reverse-phase HPLC technique. Acetonitrile (ACN) and 0.1% triethylamine (Et3N), pH 2.5, were used as a mobile phase in a 20:80 volumetric ratio to achieve separation with 1.0ml/min, at retention times of about 2.25, 3.02 and 4.38min for glycopyrronium, vilanterol and fluticasone furoate, respectively, with detection at 250nm. Validation in compliance with ICH guidelines verified adequate accuracy, precision, linearity, specificity and robustness, and forced degradation findings confirmed that the method was stability-indicating and sufficient for pharmacopeial quality control of the marketed formulation. Green assessment using the AGREE tool yielded a score of 0.58, supporting its routine use for quality control and stability evaluation of this triple combination.
Cite this article:
K.E. Pravallika, Kothapalli Narendra, P. Ravi. Development, Validation and Green Analytical Assessment of a Stability-Indicating RP-HPLC Method for Simultaneous Estimation of Glycopyrronium, Vilanterol and Fluticasone Furoate in Capsule Dosage Form. Asian Journal of Pharmaceutical Research. 2026; 16(4):371-7. doi: 10.52711/2231-5691.2026.00054
Cite(Electronic):
K.E. Pravallika, Kothapalli Narendra, P. Ravi. Development, Validation and Green Analytical Assessment of a Stability-Indicating RP-HPLC Method for Simultaneous Estimation of Glycopyrronium, Vilanterol and Fluticasone Furoate in Capsule Dosage Form. Asian Journal of Pharmaceutical Research. 2026; 16(4):371-7. doi: 10.52711/2231-5691.2026.00054 Available on: https://asianjpr.com/AbstractView.aspx?PID=2026-16-4-1
REFERENCES:
1. PubChem Compound Summary for CID 3494, Glycopyrronium. National Center for Biotechnology Information. Retrieved December 15, 2025. Available on https://pubchem.ncbi.nlm.nih.gov/compound/Glycopyrronium.
2. Adimoolam BM, Jangam A, Dadinaboyina SB, Ragampeta S, Thota JR. Stability studies of glycopyrronium bromide and in vitro toxicity evaluation of its major transformation products by LC-MS/MS and NMR. European Journal of Mass Spectrometry. 2025 May 4:14690667251339714.
3. Ridolo E, Milanese M, Barone A, Nicoletta F, Ottoni M, Cosini FF, Passalacqua G, Lombardi C. Extrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review. Therapeutic Advances in Respiratory Disease. 2025 Apr; 19:17534666251332076.
4. Patel K, Patel D, Dwivedi J, Newal P, Meshram D. A review on analytical techniques for estimation of anti cholinergic drug: Glycopyrronium bromide. Asian Journal of Pharmaceutical Analysis. 2017 Dec 24; 7(4):239-42.
5. Jin LU. Adrenergic agonist therapy and emerging acupuncture targets in asthma: A review of mechanisms and therapeutic implications. World Journal of Acupuncture-Moxibustion. 2025 Aug 5.
6. PubChem Compound Summary for CID 10184665, Vilanterol. National Center for Biotechnology Information. Retrieved December 15, 2025. Available on https://pubchem.ncbi.nlm.nih.gov/compound/Vilanterol.
7. Daley-Yates PT, Deans A, Mehta R, Sousa AR. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Pulmonary Pharmacology & Therapeutics. 2022 Dec 1; 77: 102171.
8. Murali M, Kothandan S, Chandrasekaran M, Singh SK, Kuppusamy G, Radhakrishnan A. Fluticasone and Cyclophosphamide towards the track of personalized Medicine. Research Journal of Pharmacy and Technology. 2021; 14(1): 179-84.
9. PubChem Compound Summary for CID 9854489, Fluticasone Furoate. National Center for Biotechnology Information. Retrieved December 15, 2025. Available on https://pubchem.ncbi.nlm.nih.gov/compound/Fluticasone-Furoate.
10. Golla R, Kumar K. Current Status of Ultra Long-Acting Beta Agonists in Children. Indian Pediatrics. 2025 Jul 23:1-4.
11. Patel C, Sahoo D, Sheth V, Jain MK, Koppula R, Verma S, Kumar D, Panda JK, Parmar D, Kansagra K, Pathak H. A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients with Uncontrolled Asthma. Clinical Therapeutics. 2025 Oct 29.
12. NB L, AG G, NB B, SB B. RP-HPLC Method for Simultaneous Quantification of Vilanterol and Fluticasone Furoate: Development and Validation. Eurasian Journal of Analytical Chemistry. 2024 Jan 1; 19(1).
13. Masimukku SK, Chintala R. Development and validation of stability indicating RP-HPLC method for fluticasone furoate and vilanterol in pharmaceutical formulations. Indian Drugs. 2018 Mar 1; 55(3).
14. Patel D, Namdev KK, Verma K, Gururani R, Tiwari A, Kumar P, Dewangan RP, Wabaidur SM, Sharma S, Dwivedi J. HPLC-UV and spectrofluorimetric methods for simultaneous estimation of fluticasone furoate and vilanterol in rabbit plasma: A pharmacokinetic study. Journal of Chromatography B. 2019 Nov 15; 1132:121842.
15. Kulkarni SV, Gulave VR, Musmade BD, Bhope SG, Nagar M, Panchgalle SP, More VS. Impurity Profiling Method Development, Validation, and Relative Response Factor Estimation for Fluticasone Furoate and Vilanterol Trifenatate Dry Powder Inhaler Using RP-HPLC with UV/PDA Detector. Pharmaceutical Chemistry Journal. 2025 Aug; 59(5):598-610.
16. Babu GR, Sowjanya M, Ramayyappa M, Karishma MA, Bharathi V, Swathi GR, Renuka C, Krishna GG, Lavanya M. Rapid RP-HPLC Method for Simultaneous estimation of Umeclidinium and Vilanterol in human plasma. Research Journal of Pharmacy and Technology. 2023 Mar 1; 16(3):1017-22.
17. Babu PV, Devi DA. Stability Indicating Assay Method Development and Validation by RP-UPLC with PDA detector for Simultaneous Estimation of Glycopyrrolate and Neostigmine in Pharmaceutical dosage form. Research Journal of Pharmacy and Technology. 2023 Jul 1; 16(7):3219-22.
18. REDDY BV, Vejendla A, Dittakavi R, REDDY SN. Development and validation of simultaneous estimation of glycopyrrolate and formoterol fumarate in its bulk and pharmaceutical rota caps dosage form by using RP-UPLC. International Journal of Applied Chemistry. 2020; 7(3):49-56.
19. Masimukku SK, Chintal R. Development and validation of spectrophotometric methods for simultaneous estimation of vilanterol and fluticasone furoate in pharmaceutical formulations. Asian J Pharm Clin Res [Internet]. 2017 Apr. 1 [cited 2026 Mar. 1]; 10(4): 302-5. Available from: https://journals.innovareacademics.in/index.php/ajpcr/article/view/16748
20. Anitha L, Beda DP. Implementation of quality by design and green chemistry principles to validate the stability indicating method on UHPLC for the simultaneous quantification of Glycopyrronium, Fluticasone, Vilanterol in inhaled formulation. Green Analytical Chemistry. 2024 Dec 1; 11:100160.